Capsid News and Research

RSS

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral (AAV) gene therapy design and manufacturing.

18 Sep 2024

New consensus on assessing carcinogenic risks of gene therapies

A new article in the peer-reviewed journal Human Gene Therapy describes the consensus reached by invited experts who participated in a meeting to evaluate the potential carcinogenicity of gene therapies.

30 Aug 2024

mRNA therapy shows promise for maple syrup urine disease

Researchers from the University of Pennsylvania, Perelman School of Medicine, Gene Therapy Program, and Moderna, have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease (MSUD).

22 Aug 2024

Machine learning revolutionizes gene delivery

Gene therapy could potentially cure genetic diseases but it remains a challenge to package and deliver new genes to specific cells safely and effectively. Existing methods of engineering one of the most commonly used gene-delivery vehicles, adeno-associated viruses (AAV), are often slow and inefficient.

9 Aug 2024

New method can rapidly determine virus infectivity

A new method that can rapidly determine whether a virus is infectious or non-infectious could revolutionize the response to future pandemics.

23 Jul 2024

Breakthrough malaria vaccines RTS,S and R21 poised to save thousands of lives

Research paper reviews the efficacy of the first licensed malaria vaccines, RTS,S and R21, highlighting their potential to significantly reduce childhood mortality and discussing future vaccine development strategies.

21 Jul 2024

Breakthrough gene therapy offers hope for Duchenne muscular dystrophy

A new gene therapy treatment for Duchenne muscular dystrophy shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in the future, repairing those muscles.

18 Jul 2024

MPA-CF3: A marine-derived compound disrupting COPZ1 to combat EV-A71

This study is spearheaded by researcher Wu Zhong (National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing) and Prof. Yong Qin (West China School of Pharmacy, Sichuan University).

26 Jun 2024

Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays.

From Gyros Protein Technologies AB 17 Jun 2024

How Epstein-Barr virus shapes immune responses in multiple sclerosis

Study found that EBV-specific immune responses in MS patients showed higher IgG titers and cell-mediated reactions to EBV antigens compared to healthy controls, suggesting a complex role of EBV in MS development.

9 Jun 2024

Gene therapy trial: restored hearing in children with hereditary deafness

The safety and effectiveness of binaural adeno-associated virus 1 (AAV1)-human otoferlin (hOTOF) therapy in five children with autosomal recessive deafness 9 (DFNB9).

7 Jun 2024

Why use light scattering to analyze proteins and viral vectors?

In this interview, Dr. Michelle Chen, Senior Director of Analytical Sciences at Wyatt Technology, talks to NewsMedical about how to use light scattering techniques to analyze proteins for their multi-attribute quantification (MAQ).

From Waters | Wyatt Technology 29 May 2024

Novel gene-delivery vehicle shows promise for treating brain disorders

In an important step toward more effective gene therapies for brain diseases, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that uses a human protein to efficiently cross the blood-brain barrier and deliver a disease-relevant gene to the brain in mice expressing the human protein.

16 May 2024

New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns

Study on the bioRxiv server reports that the SARS-CoV-2 KP.2 variant, despite lower infectivity, shows significant immune resistance and higher transmissibility compared to other variants, potentially impacting global public health and vaccine efficacy.

29 Apr 2024